Dr Reddys Laboratories has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a fall of 38.05% in its net profit at Rs 311.50 crore for the quarter under review as compared to Rs 502.80 crore for the same quarter in the previous year. However, total income of the company increased by 15.21% at Rs 3432.30 crore for Q4FY21 as compared Rs 2979.10 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 28.65% in its net profit and share of profit of associates at Rs 557.30 crore for the quarter under review as compared to Rs 781.10 crore for the same quarter in the previous year. However, total income of the company increased by 7.26% at Rs 4850.80 crore for Q4FY21 as compared Rs 4522.50 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a fall of 25.57% in its net profit at Rs 2186.40 crore as compared to Rs 2937.70 crore for the previous year. However, total income of the company increased by 12.36% at Rs 14150.20 crore for year under review as compared to Rs 12593.60 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a fall of 3.67% in its net profit and share of profit of associates at Rs 1951.60 crore as compared to Rs 2026.00 crore for the previous year. However, total income of the company increased by 6.62% at Rs 19338.90 crore for year under review as compared to Rs 18137.60 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1513.05 |
Dr. Reddys Lab | 5978.00 |
Cipla | 1397.50 |
Zydus Lifesciences | 931.90 |
Lupin | 1591.20 |
View more.. |